Headlands Technologies’s Intellia Therapeutics NTLA Stock Holding History

Headlands Technologies’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.59M	Buy	+94,250	New	+$1.32M	0.17%	148
2026 Q1	–	Sell	-243,903	Closed	-$2.19M	–	891
2025 Q4	$2.19M	Buy	243,903 +184,280	+309%	+$2.54M	0.18%	121
2025 Q3	$1.03M	Buy	59,623 +56,848	+2,049%	+$700K	0.08%	233
2025 Q2	$26K	Buy	+2,775	New	+$22.8K	﹤0.01%	890
2024 Q4	–	Sell	-9,241	Closed	-$190K	–	1467
2024 Q3	$190K	Buy	9,241 +6,093	+194%	+$140K	0.02%	540
2024 Q2	$70.5K	Sell	3,148 -4,994	-61%	-$119K	0.01%	715
2024 Q1	$224K	Buy	+8,142	New	+$226K	0.05%	344
2023 Q4	–	Sell	-6,273	Closed	-$198K	–	1191
2023 Q3	$198K	Sell	6,273 -7,928	-56%	-$308K	0.1%	203
2023 Q2	$579K	Buy	+14,201	New	+$576K	0.19%	134

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Headlands Technologies's NTLA Position: Q2 2026 in Review

Headlands Technologies opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 94,250 shares worth $1.59M. The stake represents 0.17% of the portfolio and ranks #148 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in NTLA as recently as Q4 2025.

Headlands Technologies first reported a position in NTLA in Q2 2023 and has held it in 9 quarters since. The position peaked at $2.19M in Q4 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Headlands Technologies held 94,250 shares of Intellia Therapeutics worth $1.59M as of Q2 2026.
Intellia Therapeutics was a new Headlands Technologies position in Q2 2026.
Intellia Therapeutics made up 0.17% of Headlands Technologies's portfolio in Q2 2026, its #148 holding.
Headlands Technologies first reported a position in Intellia Therapeutics in Q2 2023 and has held it in 9 quarters since.
Headlands Technologies's Intellia Therapeutics position peaked at $2.19M in Q4 2025.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.